Safety Pharmacology in Focus: Targeted Testing for Smarter INDs

Xiaoxia Li, MD, PhD, DABT Executive Technical Director, Toxicology, WuXi AppTec

Safety pharmacology occupies a critical, if sometimes misunderstood, niche in the drug development continuum. Designed to evaluate a compound’s undesirable effects on key physiological systems at pharmacologically relevant doses, it bridges the scientific domains of pharmacology and toxicology. Yet, for many drug developers, its precise role, optimal timing, and regulatory expectations remain unclear. Understanding when and how to conduct safety pharmacology studies can mitigate attrition risk, improve IND readiness, and reduce costly delays.

Safety Pharmacology Defined

Safety pharmacology assesses potential unwanted pharmacodynamic effects of new drug candidates on critical organ systems – particularly the cardiovascular, central nervous (CNS), and respiratory systems. Unlike general toxicology studies that emphasize, in most cases, repeat-dose and high-level exposures, safety pharmacology evaluates single-dose effects at therapeutic levels. This distinction is more than semantic. It affects study design, interpretation, and regulatory relevance, ultimately helping to uncover how new drug treatments perform in real-world patient populations.

Key characteristics that differentiate safety pharmacology:

• Dose Relevance: Tests are performed at exposures in relation to the therapeutic range and above, not toxic thresholds.
• Study Design: Most in vivo safety pharmacology studies are single dose (non-repeat-dose) and use specialized methodologies such as telemetry or behavioral observations or respiratory assessments to identify any unwanted pharmacodynamic effects.
• System Focus: The mandatory core battery studies typically focus on primary organ systems including CNS, cardiovascular, and respiratory assessments; other organ systems such as renal system and gastrointestinal system are evaluated case-by-case.
• Regulatory Intent: Intended to identify immediate and delayed effects that could signal human risk early in development.

Governed by ICH guidelines S7A and S7B¹ and closely aligned with clinical concerns addressed under E14,2 safety pharmacology studies are typically designed to concentrate on a single organ or physiological system, differing from traditional toxicology studies.

Evolving Safety Pharmacology Requirements

ICH guidance and regulatory expectations vary based on drug modality and therapeutic indication. These distinctions often help sponsors and laboratories tailor a compliant and efficient safety pharmacology program.

• Small Molecules, Non-Oncology Indications: Standalone safety pharmacology core battery studies including CNS, cardiovascular, and respiratory systems are often conducted.
• Biologics: Due to their unique pharmacological profiles such as species/tissue specificity and restriction from cross plasma membrane, biologics may qualify for reduced safety pharmacology requirements. In many cases, relevant endpoints can be embedded within GLP general toxicology studies.
• Oncology Indications: Regulators may accept a more streamlined approach for drugs targeting advanced or life-threatening cancers. Cardiovascular endpoints such as ECG monitoring can be integrated into general toxicology studies, and some CNS or respiratory evaluations may be waived if justified by the mechanism of action or patient population. However, if on – or off-target liabilities are suspected, dedicated safety pharmacology assessments could be requested.
• Study Integration: The decision to conduct standalone versus integrated studies often depends on factors such as the route of administration, anticipated systemic exposure, target population in clinic, and species selection. Flexibility in study design is allowed under ICH S7A with a scientifically sound justification.³

A well-informed approach enables fit-for-purpose design, helping to avoid unnecessary studies while ensuring regulatory compliance. Early planning also supports the ethical principles of the 3Rs (Replacement, Reduction, Refinement) by minimizing redundant animal use and optimizing study value.

Benefits of Early Integration

While safety pharmacology testing is a regulatory requirement prior to first-in-human (FIH) trials, conducting these assessments earlier – during candidate selection or lead optimization – offers significant strategic advantages:

• Reduces Downstream Risk: Early safety pharmacology studies help flag compounds with potential on – or off-target adverse effects that could lead to late-stage failure, allowing teams to pivot or optimize before committing to costly GLP toxicology or clinical studies.
• Improves Dosing Strategy: Characterizing a compound’s pharmacodynamic (PD) effects on vital systems at therapeutic dose levels could refine dosing decisions in later-stage protocols when possible.
• Facilitates Candidate Selection & Prioritization: Safety pharmacology screening can be used alongside efficacy and ADME data to select development candidates with the most favorable overall profiles. Behavioral assessments like the functional observational battery (FOB), in vitro HERG assays, and non-GLP telemetry can all contribute to go/no-go decisions.
• Strengthens Regulatory Submissions: Including safety pharmacology data early in the IND-enabling package not only satisfies ICH requirements but also demonstrates scientific diligence. Regulators may be more confident in a submission that shows a comprehensive system-level evaluation, particularly when exposure-response relationships are explored in line with E14/S7B integration.
• Promotes Cross-Functional Alignment: Early discussions of safety pharmacology strategy encourage alignment between discovery, DMPK, toxicology, and clinical teams, enabling more coordinated development and risk management.

When testing is applied deliberately, these advantages can make for a more efficient and streamlined approval process. The current methodologies, tools, and study designs reflect scientific innovation and regulatory shifts.

Evolving Methodologies

Since the issuance of ICH S7A in 2001, the safety pharmacology landscape has steadily evolved. While the foundational goal – evaluating effects on vital organ systems like the CNS, cardiovascular, and respiratory systems and/or renal and GI systems as needed – remains unchanged, regulatory expectations have become increasingly specific. Integrating ICH S7B with clinical E14 guidance has prompted new best practices, more specifically for assessing cardiovascular liability such as QT interval prolongation.⁴ As such, in recent years, it has translated into methodological advances such as jacketed telemetry or Latin square designs that enable continuous ECG, blood pressure, and body temperature monitoring across multiple doses along with blood sampling for systemic exposure assessments performed in the same study. This approach helps reduce inter-subject variability and improve clinical translation.

Regulatory agencies also anticipate that sponsors apply a weight-of-evidence approach¹ that integrates in vitro data (e.g., HERG), in vivo telemetry, and behavioral and respiratory endpoints to build a comprehensive safety profile. While alternative methods such as organ-on-a-chip and in silico models are under exploration, they have not yet replaced the need for validated in vivo testing.

Depending on the therapeutic context, safety pharmacology assessments may be integrated into general toxicology protocols. This is especially common in biologics and/or oncology programs, where fit-for-purpose designs can streamline development without compromising rigor as long as system-specific endpoints are sufficiently addressed.

These combined efforts reflect a shift toward translationally relevant, resource-efficient study designs that meet regulatory expectations and support smarter decision-making earlier in development.

Safety Pharmacology in Practice

For drug sponsors initiating safety pharmacology testing, the following best practices can help navigate complexity and avoid setbacks:

• Start Early: Early screening (e.g., in vitro HERG, cardiovascular, and/or CNS behavioral tests) can flag liabilities before advancing into GLP toxicology, especially for small molecules outside of oncology indication.
• Tailor the Strategy to the Compound: Different classes (e.g., small molecule versus biologic) and indications (e.g., oncology versus metabolic) warrant different levels of safety pharmacology testing.
• Integrate When Feasible: Depending on compound modality and/or other factors, combining safety pharmacology endpoints into general toxicology studies can be resource-efficient and scientifically valid when used appropriately.
• Maintain Flexibility: Regulators allow scientifically justified adaptations to standard study plans. Understanding these flexibilities can reduce time and costs.
• Use In-Vitro Wisely: Early off-target screening can inform decisions and prevent unnecessary investment in high-risk compounds.
• Document Clearly: Be prepared to justify approaches in IND submissions, especially if deviating from standard standalone protocols.
• Stay Current: Regulatory expectations are evolving, especially regarding exposure-response analysis. Ongoing alignment with the latest E14/S7B updates can help ensure regulatory confidence.

By following these principles, sponsors can ensure that safety pharmacology programs are compliant and strategically valuable.

A Final Word on the Road to IND Approval

Safety pharmacology is more than a checkbox in the IND timeline – it is a dynamic, data-rich discipline that plays a strategic role in modern drug development. By aligning study design with evolving regulatory guidance, integrating early screening assays, and leveraging both traditional and emerging methodologies, sponsors can make better-informed decisions that reduce risk, conserve resources, and support faster progression to patients. Whether conducted as standalone studies or integrated into general toxicology, safety pharmacology assessments provide critical insights that translate to safer, more efficient therapeutic development.

Subscribe to our e-Newsletters
Stay up to date with the latest news, articles, and events. Plus, get special
offers from American Pharmaceutical Review delivered to your inbox!
Sign up now!